← Back
Data updated: Jun 28, 2026
RESILIA PHARMS
Pharma Pharmaceuticals
RESILIA PHARMS is a pharmaceutical company with 1 FDA-approved products.
2013
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
RESILIA PHARMS's Key Drugs
RESILIA PHARMS's core commercial portfolio centers on ECOZA — its most strategically important drugs approved in the last 15 years.
RESILIA PHARMS's Recent FDA Approvals
New NDA/BLA approvals for RESILIA PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
RESILIA PHARMS's Therapeutic Areas
Disease areas where RESILIA PHARMS has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
RESILIA PHARMS Pipeline Snapshot
Active clinical trials for RESILIA PHARMS across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • ECOZA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2013-10-24
- Latest
- 2019-11-18
- Applications
- 1